1 / 16

Anti-Ischaemic Medications

Learn about the pharmacological interventions for ischaemic heart disease, including the use of β-blockers and nitrates. Understand their actions, clinical uses, contraindications, and potential adverse effects.

leemclean
Télécharger la présentation

Anti-Ischaemic Medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anti-Ischaemic Medications β Blockers and Nitrates by: Mimoza Meholli 9/17/2003

  2. Case 1 • A 62 yr old male with a history of chronic Stable Angina since 1998 complains of chest pain radiating to the neck, left arm and back, occurring at rest. • Patient has DM-2, HTN, Duodenal ulcer and Hypothyroidism. • EKG shows evidence of previous inferior wall MI.

  3. Pharmacological Intervention in Ischaemic Heart Disease AIMS: • Increase coronary blood flow. • Reduce myocardial energy requirements. • To stop or reverse coronary artery occlusion in order to avoid or minimize myocardial cell death.

  4. β -Blockers • Competitively antagonize the action of catecholamines at β -adrenergic receptors. • Decrease heart rate, stroke volume, and cardiac output. • Normal sympathetic control of bp is maintained in HTN due to unopposed vasoconstriction by ά-receptors, thus avoiding orthostatic hypotension. • Carvediolol sensitizes down regulated β-receptors in CHF, making mayocytes responsive to catecholamines and improves ventricular function.

  5. Pharmacokinetics • Variable: depends on preparation, hepatic metabolism, renal elimination and lipid solubility. • Generally, β-Blockers have a short half-life (~4hrs), but long acting preparations are available.

  6. Clinical Use/Indications Hypertension Glaucoma Migraine Hyperthyroidism Angina Pectoris Myocardial Infarction Compensated CHF Contraindications Asthma/bronchospasm Uncompensated CHF Bradychardia Cardiogenic shock AV conduction abnormalities

  7. Adverse effects: • Bronchostriction • Arrhythmias • Sexual impairment/depression • Disturbances in metabolism • masks signs of acute hypoglycemia and hyperthyroidism; • abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm. • Caution/monitor closely in: • Wolff-Parkinson-White syndrome and renal or hepatic dysfunction

  8. Drug Interactions • Aluminum salts • Barbiturates • NSAIDs • Penicillins • Calcium salts • Cholestyramine, and Rifampin may decrease effects • Calcium channel blockers, Cimetidine, Loop Diuretics, and MAOIs may increase toxicity • May increase toxicity of: Hydralazine, Haloperidol, Benzodiazepines, and Phenothiazines

  9. βBlocker Brand USA Brand ISRAEL PO Doze, mg T1/2 hrs Actions/ Selectivity Atenolol Tenormin Normitem 50-100 qd 6-9 β1 Metoprolol Lopressor Metopress Neobloc 50-100 Bid 3-4 β1 Acebutulol Sectral Sectral 200-600 Bid 3-4 β1 ,ISA Propanolol Inderal Deralin 20-80 qd 4-6 β1 β2 Nadolol Cogard N/A 40-160 qd 10-24 β1 β2 Timolol Blocarden N/A 10-20 bid 3-4 β1 β2 Pindolol Visken Pinden 5-20 tid 3-4 β1 β2 ISA Carvedilol Coreg Dimitone 25-50 bid 7-10 α1 β2 β1 Labetolol Normodyne Trandate 100-600 bid 6-8 α1 β2 β1

  10. Nitrates Mode of Action: • Smooth muscle relaxation • Nitric oxide stimulates guanylyl cyclase, which increases intracellular cGMP leading to relaxation. • Preload (venules) and Afterload (arterioles) are reducedbp and CO • Direct coronary artery dialation ischeamic pain

  11. Pharmacokinetics • Large first-pass effect • Short half-lives, 1-5 min (except isosorbide mononitrate, 5 hrs) • Large individual variations in blood concentrations • Preparations available: IV, sublingual, PO, transdermal

  12. Clinical use/Indications Acute Angina attacks: administered sublingually Prophylaxis: slow release preparations used as maintenance therapy to prevent angina IV used to control unstable angina, or threatened MI Contraindications Documented hypersensitivity Severe Anemia Closed-angle Glaucoma Orthostatic hypotension Head trauma Cerebral hemorrhage Constrictive Pericarditis Coronary Pulmonade and Arterial Hypoxemia Hypotensive Shock

  13. Adverse Effects • Doze related: • Orthostatic Hypotension • Flushing • Headache • Precautions: • Tolerance to vascular and antianginal effects of nitrates may develop • minimize tolerance by using smallest effective dose or pulse therapy (intermittent dosing), or by alternating with other coronary vasodilators • Caution when administering to patients with glaucoma

  14. Drug Interactions • Alcohol may cause severe hypotension and cardiovascular collapse • Aspirin may increase serum concentrations and actions • Calcium channel blockers may increase symptomatic orthostatic hypotension (adjust dose of either agent) • May decrease effects of Heparin

  15. Nitrate Brand USA Brand ISRAEL Doze, mg Onset min T1/2 Subl. Nitroglycerin Nitrostat Angised 0.3-0.6 2-5 10-30 min Aerosol Nitroglycerin. Nitrolingual Nitrolingual 0.4 2-5 10-30 min Sublingual Isosorbide dinitrate Isodril N/A 2.5-10 10-30 1-2 hr Oral Isosorbide Dinitrate Sorbitrate Isotard 5-40 30-60 4-6 hr Oral Isosorbide Mononitrate Monoket Monocord 10-20 30-60 6-8 hr Oral Sustained Release Nitroglycerin Nitroglyn, Nitro-Time N/A 2.5-9 30-60 3-8 hr Transdermal. Nitrog. Patch Nitro-Dur Trinipatch 5-15 >60 12-14 hr 2% Nitroglyc. Ointment Nitrol 2% N/A 0.5-2 inches 20-60 3-8 hr

  16. References • The Washington Manual of Medical Therapeutics, 30th ed. • Lippincott’s Review of Pharmacology, 2000. • Gibbson R, et al. Guidelines for the Management of Patients with Chronic Stable Angina:Treatment. Ann. Intern. Med. 2001;135:616-632.

More Related